Replies to post #50836 on STOCK GOODIES PLAYS OF THE WEEK

[Komando Robot]

MFTH DD Sheet ~














Business Summary


Medisafe 1 Technologies Corp., a development stage company, plans to develop a commercial application of the design in a patent titled Protector for administering medicine , which is a device that prevents errors in administering medications. The company was incorporated in July 2009 and is based in Jerusalem, Israel.


Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.














Share Structure


Market Value1 $4,552,265 a/o Jun 02, 2011
Shares Outstanding 56,903,309 a/o May 16, 2011
Float Not Available
Authorized Shares 200,000,000 a/o Mar 31, 2010
Par Value 0.0001
source: otc and confirmed via email per TA








Patented technologies





Use physical locking and barcodes on the patient’s armband to ensure that only the correct prescription medication is administered, reported a much-coveted endorsement from Israel’s Pharmaceuticals Administration (IPA) for the Company’s barcoded syringe locking device.


http://www.freepatentsonline.com/7347841.pdf











Medisafe 1 Technologies Corp. (MFTH.OB) Device Endorsed for National Implementation by Israeli Pharmaceuticals Administration
January 10, 2011 8:41 PM SAST


http://africa.ibtimes.com/articles/99305/20110111/medisafetechnologies-corp-mfth-ob-device-endorsed-for-national-implementation-by-israeli-pharmaceuti.htm





Industry Overview


According to the World Health Organization (WHO), approximately 12 billion preventive and curative injections are given each year in the U.S. and Europe, equating to 40 million injections each day. While the WHO does not provide individual statistics for injection use in the United States specifically, it is clear that a very modest or minimum calculation would suggest that the Medisafe device could easily be used tens of millions of times annually.


In many cases, the hypodermic needle assembly is prepared in advance and stored until use, perhaps in a cabinet or refrigerator. A medical professional may have instructions for administering a certain medicine hypodermically to a specific patient. However, there is a chance that the medical practitioner may inadvertently select the incorrect needle assembly from the cabinet or refrigerator and consequently administer the incorrect medicine to the patient. The results of this kind of error can be serious and even fatal.


(as posted in MFTH recent S-1: http://www.otcmarkets.com/stock/MFTH/financials)





Headline News


source: http://www.otcmarkets.com/stock/MFTH/news





May 17, 2011 Medisafe 1 Technologies Initiates Negotiations for the Acquisition of a Major Medical (Patent Pending) Breakthrough Technology


Apr 14, 2011 Medisafe 1 Technologies Closes $5 Million Equity Funding Agreement


Apr 11, 2011 Medisafe 1 Technologies to Sign Agreement for $5 Million Funding Commitment


Apr 4, 2011 Medisafe 1 Technologies Garners Interest From Multinational Medical Supplier Becton, Dickinson and Company


Mar 21, 2011 Medisafe 1 Technologies Receives an Unsolicited Buyout at $0.33 Per Share


Mar 15, 2011 Medisafe 1 Technologies has Been Approached for a Buyout at $0.33 Per Share








Background of officers and Directors


Jacob Elhadad
Mr. Elhadad has been President and Director since the Company’s inception on July 7, 2009. From September 1990 until August 1994 Mr. Elhadad studied in the Talmudic Biblical Institution, Bet Hatalmud, Jerusalem, Israel, where he received his Bachelor of Arts in Biblical History Science and Talmudic Studies. From September 1994 until August 1997 he continued his religious studies in the Higher Educational Talmudic Center ‘Ponavitz School of Talmudic Studies’, Bnei Berak, Israel, where he received his Honorable Rabbinical Degree. In September 1997 he continued his studies in the Ramat Gan, Israel University, in Business Management and Economics, until August 1999. From September 1999 until January 2001 he served as a strategic consultant to the Member of the Israeli Government Parliament, Ministry of Interior. From February 2001 until present Mr. Elhadad served as Chief Executive Officer of Jelmm Trade LTD, in Jerusalem, Israel, an international Diamond and Jewelry Co., while continuing to serve part time as a strategic consultant to various members of the Israel Government Parliament.


The Board believes that Mr. Elhadad ’ s educational background and his extensive experience in business development make him a valuable director. The Board believes that Mr. Elhadad’s business experience and skills will enable him to assist the company through its development stage and thereafter to achieve its goals and business objectives.


Yisrael Gottlieb
Mr. Gottlieb has served as Secretary and Director and Internal Accounting and Financial Officer since July 7, 2009. From September 1999 until August 2003 Mr. Gottileb studied religious studies in the Talmudic University “Gur”, in Haifa, Israel. From September 2004 until present Mr. Gottlieb was assisting as a consultant to various companies in Patent Designs and related Product Development and Enhancements and Operations.





Contact Info





MEDISAFE 1 TECHNOLOGIES CORP
216 JAFFA STREET
JERUSALEM
ISRAEL
SECOND FLOOR
TEL: [phone]
FAX: [phone]
http://www.medisafe1.com/